Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -76% Improvement Relative Risk Ventilation -112% Mahajan et al. Remdesivir for COVID-19 RCT LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? RCT 70 patients in India Higher mortality (p=0.47) and ventilation (p=0.42), not stat. sig. Mahajan et al., Indian J. Anasthesia, doi:10.4103/ija.IJA_149_21 Favors remdesivir Favors control
Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
Mahajan et al., Indian Journal of Anasthesia, doi:10.4103/ija.IJA_149_21
Mahajan et al., Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised.., Indian Journal of Anasthesia, doi:10.4103/ija.IJA_149_21
Mar 2021   Source   PDF  
  All Studies   Meta
Small RCT with 34 remdesivir patients and 36 controls finding no significant difference in clinical outcomes.
[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 76.5% higher, RR 1.76, p = 0.47, treatment 5 of 34 (14.7%), control 3 of 36 (8.3%).
risk of mechanical ventilation, 111.8% higher, RR 2.12, p = 0.42, treatment 4 of 34 (11.8%), control 2 of 36 (5.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mahajan et al., 20 Mar 2021, Randomized Controlled Trial, India, peer-reviewed, 3 authors, average treatment delay 6.84 days.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: Original Article Clinical outcomes of using remdesivir in patients with moderate to severe COVID‑19: A prospective randomised study Address for correspondence: Dr. Lakshmi Mahajan, Department of Anaesthesia, SGRD Medical College and Hospital, 166 e block, Ranjit Avenue, Amritsar –143 001, Punjab, India. E‑mail: drlakshmimahajan@ Submitted: Revised: Accepted: Published: 18‑Feb‑2021 03‑Mar‑2021 09‑Mar‑2021 20-Mar-2021 Access this article online Website: DOI: 10.4103/ija.IJA_149_21 Quick response code Lakshmi Mahajan, A P Singh, Gifty Department of Anaesthesia, Sri Guru Ram Das (SGRD) Medical College and Hospital, Amritsar, Punjab, India ABSTRACT Background and Aims: When the world was frantically searching for a drug effective against the coronavirus disease (COVID)‑19, remdesivir, a broad‑spectrum anti‑viral medication, became a part of the COVID treatment. We planned a study to evaluate improvement in clinical outcomes with remdesivir treatment for five days. Methods: Participants more than 40‑years old and with moderate to severe COVID‑19 but not on mechanical ventilation were randomly assigned into two groups‑remdesivir group (34 cases) to receive the study drug intravenous (IV) remdesivir for five days plus the standard care (SC) and non‑remdesivir group (36 cases) to receive the SC but not to receive the study drug. Follow‑up was continued for 12 days after the beginning of treatment or until discharge/death. Patient’s clinical status was assessed by laboratory investigations and physical examination (from day 1 to day 12 on a 4‑point ordinal scale and from day 12 to 24 on a 6‑point ordinal scale). Oxygen support requirements and adverse events were recorded. The data were entered and analysed using Statistical Package for the Social Sciences (SPSS) version 22.0. Results: High‑flow oxygen support and non‑invasive ventilation was required at baseline by lesser patients in the remdesivir group. In the end, both groups had similar outcomes after adjustment for baseline clinical status. There was no statistical difference in mortality between the two groups (p = 0.749). Patients in both groups had an equal time to recovery. There was no difference in the occurrence of adverse effects of remdesivir between the two groups. Conclusion: Remdesivir therapy for five days did not produce improvement in clinical outcomes in moderate to severe COVID‑19 cases. Key words: COVID‑19, remdesivir, treatment outcome
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop